Share

January 08, 2019; 92 (2) Editorial

ECG monitoring after acute ischemic stroke

Does patient selection matter?

Mira Katan, Steven A. Lubitz
First published December 7, 2018, DOI: https://doi.org/10.1212/WNL.0000000000006719
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
107

Share

Article Information

vol. 92 no. 2 65-66
DOI: 
https://doi.org/10.1212/WNL.0000000000006719
PubMed: 
30530795
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • First Published December 7, 2018.

Article Versions

Copyright & Usage: 
© 2018 American Academy of Neurology

Author Disclosures

    1. Mira Katan, MD, MS and
    2. Steven A. Lubitz, MD, MPH
  1. Mira Katan, MD, MS and
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Speaker Honoraria for presentation of data of the COSMOS study (Clinical Trials. gov number, NCT00390962) from BRAHMS,Berlin 2009.

    Editorial Boards:

    1. STROKE, section editor, since 2017

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. I received within the last 9 years an unrestricted research grants from BRAHMS/ Thermo Fisher Scientific (in 2009).

    Research Support, Government Entities:

    1. I received within the last 5 years research grants from the Swiss National Science Foundation (PZ00P3_142422). Moreover I am receiving a career developing grant form the Spital-Pool of the University Hospital of Zurich (2017-2019)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. I received a transatlantic career award from the Fondation Leducq and support form the Swiss Heart Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Steven A. Lubitz, MD, MPH
    3. Scientific Advisory Boards:

    1. (1) 05/2016, 05/2017 Advisory BoardSt. Jude Medical / Abbott(2) 11/2017 Advisory BoardBristol-Myers Squibb

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) 02/2017ConsultantQuest Diagnostics

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Bristol Myers Squibb / Pfizer, (2) Bayer HealthCare(3) Boehringer Ingelheim(4) Biotronik

    Research Support, Government Entities:

    1. (1) NIH 1K23HL114724, 1R01HL139731

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) American Heart Association 18SFRN34250007(2) Doris Duke Charitable Foundation 2014105, 2016077, 2017039

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology (M.K.), University Hospital of Zurich, Switzerland; and Cardiac Arrhythmia Service and Cardiovascular Research Center (S.A.L.), Massachusetts General Hospital, Boston.
  1. Correspondence
    Dr. Katan mira.katan{at}usz.ch
View Full Text

Article usage

Article usage: December 2018 to June 2019

AbstractFullPdfSource
Dec 2018291023Highwire
Jan 20193057348Highwire
Feb 201986149Highwire
Mar 20191471013Highwire
Apr 201917857Highwire
May 201910833Highwire
Jun 201910324Highwire

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me